Lyrica FDA Approval History
FDA Approved: Yes (First approved December 30, 2004)
Brand name: Lyrica
Generic name: pregabalin
Dosage form: Capsules
Company: Pfizer Inc.
Treatment for: Neuropathic Pain, Postherpetic Neuralgia, Fibromyalgia, Diabetic Peripheral Neuropathy, Epilepsy
Lyrica (pregabalin) is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia and spinal cord injury; as an adjunctive therapy for partial onset seizures and for the treatment of fibromyalgia.
Development timeline for Lyrica
| Date | Article |
|---|---|
| Oct 12, 2017 | Approval FDA Approves Lyrica CR (pregabalin) Extended-Release Tablets for Neuropathic Pain Conditions |
| Jun 21, 2012 | Approval FDA Approves Lyrica For The Management Of Neuropathic Pain Associated With Spinal Cord Injury Based On Priority Review |
| Jun 22, 2007 | Approval FDA Approves First Drug for Treating Fibromyalgia - Lyrica |
| Dec 31, 2004 | Approval Lyrica Pfizer Inc. - Treatment for Neuropathic Pain |
| Sep 2, 2004 | Pfizer Statement on Regulatory Status of Lyrica |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
